AAD: Significant benefits seen for brepocitinib 30 mg in dermatomyositis
For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study published online March 28 in ...
15 hours ago
0
1







